129 related articles for article (PubMed ID: 9633842)
21. Clinicopathology of malignant surface epithelial neoplasms of the ovary.
Hendrickson MR; Longacre TA; Kempson RL
Pathology (Phila); 1993; 1(2):367-410. PubMed ID: 9420924
[TBL] [Abstract][Full Text] [Related]
22. Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer.
Psyrri A; Bamias A; Yu Z; Weinberger PM; Kassar M; Markakis S; Kowalski D; Efstathiou E; Camp RL; Rimm DL; Dimopoulos MA
Clin Cancer Res; 2005 Dec; 11(23):8384-90. PubMed ID: 16322299
[TBL] [Abstract][Full Text] [Related]
23. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
[TBL] [Abstract][Full Text] [Related]
24. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
25. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival.
Chen CA; Cheng WF; Lee CN; Chen TM; Kung CC; Hsieh FJ; Hsieh CY
Gynecol Oncol; 1999 Aug; 74(2):235-40. PubMed ID: 10419737
[TBL] [Abstract][Full Text] [Related]
26. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study.
Akahira JI; Yoshikawa H; Shimizu Y; Tsunematsu R; Hirakawa T; Kuramoto H; Shiromizu K; Kuzuya K; Kamura T; Kikuchi Y; Kodama S; Yamamoto K; Sato S
Gynecol Oncol; 2001 Jun; 81(3):398-403. PubMed ID: 11371128
[TBL] [Abstract][Full Text] [Related]
28. Optimal debulking surgery is an independent prognostic factor in patients with FIGO IIIC primary epithelial ovarian carcinoma.
Wang PH; Yuan CC; Shyong WY; Chiang SC; Chao JY; Yen MS; Ng HT
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar; 63(3):220-5. PubMed ID: 10746418
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis.
Psyrri A; Yu Z; Bamias A; Weinberger PM; Markakis S; Kowalski D; Camp RL; Rimm DL; Dimopoulos MA
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1179-83. PubMed ID: 16775178
[TBL] [Abstract][Full Text] [Related]
30. Pathology of epithelial ovarian cancer.
Tornos C; Silva EG
Obstet Gynecol Clin North Am; 1994 Mar; 21(1):63-77. PubMed ID: 8015767
[TBL] [Abstract][Full Text] [Related]
31. VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection.
Engels K; du Bois A; Harter P; Fisseler-Eckhoff A; Kommoss F; Stauber R; Kaufmann M; Nekljudova V; Loibl S
J Clin Pathol; 2009 May; 62(5):448-54. PubMed ID: 19126566
[TBL] [Abstract][Full Text] [Related]
32. GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer.
Kolwijck E; Zusterzeel PL; Roelofs HM; Hendriks JC; Peters WH; Massuger LF
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2176-81. PubMed ID: 19661073
[TBL] [Abstract][Full Text] [Related]
33. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
Orr JW; Orr P; Kern DH
Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
[TBL] [Abstract][Full Text] [Related]
34. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer.
Aletti GD; Dowdy SC; Gostout BS; Jones MB; Stanhope CR; Wilson TO; Podratz KC; Cliby WA
Obstet Gynecol; 2006 Jan; 107(1):77-85. PubMed ID: 16394043
[TBL] [Abstract][Full Text] [Related]
35. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.
Paramasivam S; Tripcony L; Crandon A; Quinn M; Hammond I; Marsden D; Proietto A; Davy M; Carter J; Nicklin J; Perrin L; Obermair A
J Clin Oncol; 2005 Sep; 23(25):5938-42. PubMed ID: 16087942
[TBL] [Abstract][Full Text] [Related]
36. Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells.
Kimmig R; Wimberger P; Hillemanns P; Kapsner T; Caspari C; Hepp H
Gynecol Oncol; 2002 Jan; 84(1):21-31. PubMed ID: 11748971
[TBL] [Abstract][Full Text] [Related]
37. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
Sillanpää S; Anttila MA; Voutilainen K; Tammi RH; Tammi MI; Saarikoski SV; Kosma VM
Clin Cancer Res; 2003 Nov; 9(14):5318-24. PubMed ID: 14614016
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors in ovarian cancer.
de Souza PL; Friedlander ML
Hematol Oncol Clin North Am; 1992 Aug; 6(4):761-82. PubMed ID: 1500385
[TBL] [Abstract][Full Text] [Related]
39. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
40. Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer.
Duncan TJ; Rolland P; Deen S; Scott IV; Liu DT; Spendlove I; Durrant LG
Clin Cancer Res; 2007 Jul; 13(14):4139-45. PubMed ID: 17634541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
